Printer Friendly

Multicenter Study of Cronobacter sakazakii Infections in Humans, Europe, 2017.

Cronobacter sakazakii is a motile, gram-negative, rodshaped opportunistic pathogen of the family Enterbacteriaceae (1). In 2007, organisms previously classified as Enterobacter sakazakii were reassigned to the new genus Cronobacter, which now consists of 7 species: C. sakazakii, C. condimenti, C. dublinensis, C. malonaticus, C. muytjensii, C. turicensis, and C. universalis (2,3). C. sakazakii has been isolated from various environments (e.g., domestic environments and manufacturing plants), clinical sources (e.g., cerebrospinal fluid, blood, and sputum), food (e.g., cheese, meat, and vegetables), and animals (e.g., rats and flies) (4,5).

Most reported cases of illness caused by C. sakazakii are in infants <2 months old (6,7). Premature infants and infants with underlying medical conditions are at the greatest risk for illness. Numerous outbreaks caused by C. sakazakii have been traced to contaminated powdered infant formula (8). Powdered infant formula is not a sterile product, and the ability of C. sakazakii to tolerate dry conditions enables it to survive for long periods in the final powdered product (9).

The screening of food (particularly powdered formula) was proposed to reduce the risk to neonatal and infant health (10,11). The most common syndromes of foodborne infection in infants include necrotizing enterocolitis (NEC), bacteremia, and meningitis (12,13). Examples of outbreaks of illness in hospital neonatal units caused by C. sakazakii associated with powdered infant formula have been compiled by Iversen and Forsythe (6) and by Lund (8).

A few cases of illness (usually nongastrointestinal) in adults caused by C. sakazakii have been reported. In most of these cases the adults had underlying diseases, and no evidence of foodborne transmission was reported (14,15).

We performed a multicenter study of C. sakazakii infections in humans (EUCRONI) to determine the occurrence of C. sakazakii in clinical microbiology laboratories across Europe. We also assessed the extent of clonality for human C. sakazakii isolates.

Material and Methods

Study Design

EUCRONI consisted of national coordinators (EUCRONI study group members) from 24 countries in Europe. Coordinators had to actively approach all medical microbiology laboratories to collect human C. sakazakii isolates (1 per patient) in their respective countries during 2017. Human historical isolates (with isolation dates before 2017) were also accepted. The 24 participating countries were arbitrarily chosen to reflect a wide geographic and socioeconomic range (Figure 1). Isolates were transferred to the study center (Austrian Agency for Health and Food Safety, Vienna, Austria) for whole-genome sequencing (WGS), matrix-assisted laser desorption/ionization timeof-flight (MALDI-TOF) mass spectrometry (MS) analysis, and antimicrobial drug susceptibility testing. We submitted data capture forms to national coordinators to collect the following demographic data: patient age and sex, patient status (colonized or infected), specimen source, type of healthcare facility requesting the microbiologic culture, and date of specimen collection.

Species Identification and DNA Extraction

We cultured isolates on Columbia blood agar plates (bio-Merieux, http://www.biomerieux.com/) overnight at 37[degrees]C. We performed species identification by using MALDITOF Biotyper (Bruker, https://www.bruker.com) and MBT Compass IVD 4.1.60 (Bruker) according to the manufacturer's instructions. We conducted isolation, quantification, and WGS of genomic DNA according to methods described by Lepuschitz et al. (16). We used Sequencing Coverage Calculator (http://www.illumina.com) for calculation of a desired mean coverage of [greater than or equal to]80-fold.

WGS Data Analysis

We de novo assembled raw reads by using SPAdes version 3.9.0 (17) and processed them in SeqSphere+ (Ridom GmbH, https://www.ridom.de) for bacterial typing. We deposited the genome sequences in the PubMLST Cronobacter database (https://pubmlst.org/Cronobacter) under accession nos. 2403 and 2495-2552. To determine the core genome multilocus sequence type (cgMLST) gene set, we performed a genome-wide gene-by-gene comparison by using the MLST+ target definer function of SeqSphere+ as described previously (18) with default parameters and the complete genome of C. sakazakii strain ATCC BAA894 (19) as reference genome, all complete C. sakazakii genomes available at GenBank, 8 isolates retrieved from whole-genome shotgun sequencing projects, and 4 C. sakazakii isolates sequenced at the Austria study center as query genomes. We extracted sequences of the 7 genes comprising the allelic profile of the classical MLST scheme and queried them against the C. sakazakii MLST database (1), assigning classical sequence types (STs) in silico. We obtained additional species confirmation by using JSpeciesWS (20) and ribosomal MLST (21). We included 23 C. sakazakii historical isolates from 4 different outbreaks (F. Allerberger, 2016; F. Barbut, 2010-2016; G. Feierl, 2009; D. Pierard, 1997-1998, all unpub. data; Appendix Table 1, https:// wwwnc.cdc.gov/EID/article/25/3/18-1652-App1.xlsx) and 3 reference strains, ATCC BAA-894 (19), ATCC29544 (PRJNA224116), and NCTC 8155 (PRJNA224116), to determine the level of microevolution.

Antimicrobial Resistance Testing

We performed in vitro susceptibility testing with the VITEK 2 Compact System (bioMerieux) and interpreted the VITEK 2 AST196 card according to European Committee on Antimicrobial Susceptibility Testing criteria for Enterobacteriaceae (Clinical Breakpoint Tables version 8.0, http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents). For detection of antibiotic resistance genes, we used the Comprehensive Antibiotic Resistance Database (22) with default settings "perfect" and "strict" for sequence analysis. We tested isolates in SeqSphere+ for Cronobacter-specific variant ampC (e.g., CSA-1, CSA-2, CMA-1, and CMA-2) (23).

Results

Strain Collection and Primary Species Identification

During the study period, 11 of 24 national coordinators (Figure 1) provided 77 presumptive C. sakazakii isolates previously identified by conventional biochemical testing, local MALDI-TOF MS analysis (Bruker Biotyper and VITEK MS), locally performed Cronobacter genusand species-specific PCRs, or 16S rRNA gene sequence analysis. These 77 isolates consisted of 36 human isolates from 2017 and 41 historical human isolates obtained during 1964-2016. The participating laboratories, using local conventional phenotypical methods or local MALDI-TOF MS analysis, incorrectly identified 18 (23.4%) of 77 human isolates as C. sakazakii.

MALDI-TOF MS analysis in the study center identified 69 of 77 isolates as C. sakazakii; 1 isolate from 2017 yielded low-confidence identification (log[score] value 1.70-1.99). We assigned 7 clinical isolates from 2017 and 1 historical clinical isolate from 2005 to other species (Table 1). The WGS-based species identification using JSpeciesWS and rMLST confirmed MALDI-TOF MS identification results in all but 10 of the 69 isolates. WGS indicated that 5 isolates were C. malonaticus, 2 were C. turicensis, 1 was C. dublinensis, 1 was C. universalis, and 1 was Siccibacter turicensis (Table 1; Appendix Table 1).

Human C. sakazakii Isolates Collected in 2017

In total, 21 C. sakazakii isolates from 21 patients were collected in 2017 in 9 participating countries in Europe. Casefatality ratio (within 30 days after specimen collection) was 2 of 21 case-patients (Table 2).

Molecular Typing of Bacterial Isolates

The defined cgMLST gene set consisted of a total of 2,831 core and 1,017 accessory targets. Of 77 sequenced isolates, 59 isolates were confirmed as C. sakazakii. These isolates had on average 99.4% of good core genome targets (97.7% to 99.9%) (18) and revealed in total 17 different sequence types (STs) (Table 3).

Core genome comparison of 59 C. sakazakii isolates and the 3 reference strains revealed an average allelic difference of 2,402 and a maximum allelic difference of 2,724 (Figure 2). Isolates clustered in the minimum- spanning tree to their respective MLST. Eight isolates belonging to ST1 included 2 stool isolates from neonates with a common epidemiologic link in Austria in 2009; these 8 isolates showed 1 allelic difference and were most closely related (203 alleles difference) to reference ATCC BAA-894, an isolate collected from powdered formula in the United States in 2001. That outbreak affected 2 neonates with necrotizing enterocolitis (both male, age 10 days and 12 days) hospitalized in the same neonatal intensive care unit.

Twelve isolates belonged to ST4, of which 3 were confirmed isolates from infants. Two infant isolates belonged to an outbreak cluster with a common epidemiologic link detected in Austria in 2016; these isolates shared the same cgMLST profile and showed a maximum of 47 allelic differences to the historical reference strain NCTC 8155 (from milk, United Kingdom, 1950). This outbreak again affected 2 neonates (neonate A: female, age 22 days, positive blood culture, fatal outcome; neonate B: male, age 16 days, positive respiratory tract specimen) hospitalized in the neonatal intensive care unit of another hospital in Austria. The third infant isolate was a 2017 ST4 isolate from a case in Austria with a fatal outcome and was most closely related (302 allelic differences) to a historical strain from Denmark isolated in 2003.

Six clinical isolates assigned to ST8 consisted of 2 historical human isolates from Canada (date of isolation unknown). These 6 isolates shared the identical core genome profile and had 1 allelic difference to reference strain ATCC29544 (from an infant, United States, 1970).

Nine human isolates assigned to ST21 comprised historical outbreak cluster from France collected during 20102016. The outbreak included 3 female patients (mean age 62 years) and 5 male patients (mean age 68 years); initial specimens were abscess material from the digestive tract (n = 1), ascites fluid (n = 1), respiratory tract specimens (n = 2), and rectal swab specimens (n = 4). Eight of these 9 isolates showed the same core genome genes, and 1 yielded 1 allelic difference.

All 10 isolates assigned to ST155 belonged to a historical outbreak among infants in Belgium during 1997-1998; the isolates originated from blood cultures (n = 2), stool specimens (n = 2), rectal swab specimens (n = 4), and respiratory tract specimens (n = 2). The first positive sample was collected in November 1997; the remaining 9 specimens were obtained during August-September 1998. Eight of the 10 isolates shared the same cgMLST profile, and 2 had 1 allelic difference.

In total, 27 of 38 historical isolates were most closely related ([less than or equal to] 1 allelic difference) to other historical isolates; 11 were singletons. All 21 isolates collected in 2017 were singletons, and no close relatedness was evident ([greater than or equal to]100 allelic differences) between historical isolates and isolates from 2017.

In Vitro and In Silico Antimicrobial Resistance Analysis

In vitro susceptibility testing of 21 human C. sakazakii isolates from 2017 revealed 20 C. sakazakii isolates that were susceptible to all 14 tested antibiotics (Appendix Table 2). One isolate was resistant to ampicillin, cefotaxime, gentamicin (intermediate), moxifloxacin, and trimethoprim/ sulfamethoxazole.

Of 21 C. sakazakii isolates, 12 isolates carried the efflux genes emrB, msbA, patA, regulatory systems modulating antibiotic efflux CRP, marA, emrR, marR, H-NS, antibiotic target protection gene msrB, and the determinant of fosfomycin resistance glpT. Seven isolates had in addition the antibiotic protection gene vgaC. One isolate had also the efflux gene norB, the antibiotic inactivation gene fosX, and the antibiotic target alteration gene mprF. One isolate had the additional antibiotic inactivation genes aac(6')-Ib-cr, aadA16, aadA2, ant(2'')-Ia, arr-3, catB3, CTX-M-9, OXA-1, the antibiotic target protection gene qnrAl, and the antibiotic target replacement gene sull.

The presence of variant ampC was confirmed for all 21 isolates. Seventeen isolates harbored CSA-2, and 4 isolates harbored CSA-1 (Appendix Table 2).

Discussion

The aim of our 2017 C. sakazakii study was to assess the occurrence of this opportunistic pathogen in countries of Europe, characterize the isolates, and recognize possible multinational outbreaks. Our finding that only 59 of 77 presumptive C. sakazakii isolates had the species-identification C. sakazakii confirmed at the central study center shows that correct identification of Cronobacter spp. is still a challenge for many routine laboratories.

The prevalence of reported C. sakazakii cases was low, with only 11 (45.8%) of 24 participating countries submitting C. sakazakii isolates. Clinical isolates from 2017 showed high genetic diversity, indicating that neither multinational nor national outbreaks occurred in 2017 in the 24 countries studied. However, characterization of the historical isolates obtained during this study confirmed occurrence of 4 previously unpublished historical outbreaks: 2 outbreaks from 2009 and 2016 in Austria, 1 from Belgium during 1997-1998, and 1 from France during 2010-2016. Hospitals affected by nosocomial C. sakazakii outbreaks might still be reluctant to publish possibly food-related outbreaks or nosocomial infections, especially in the case of affected infants and particularly in the case of related fatalities.

Strain typing using classical MLST identified a total of 17 STs among 59 sequenced C. sakazakii isolates. Our addition of a new ad hoc cgMLST scheme consisting of 2,831 core target genes provides more discriminative power for outbreak investigation and source tracking than the standard 7-loci MLST scheme.

The dominant STs found among our clinical C. sakazakii isolates from 2017 were ST4, ST17, ST1, and ST40, a distribution consistent with results from other studies (1). The medical literature often links C. sakazakii ST4 with powdered infant formula-associated outbreaks in infants (3). In our study, the sole strain (7750-17) affecting an infant (a 3-month-old baby boy who died) was ST4, isolated from a blood culture.

Antibiotic treatment is essential in the care of a patient with a confirmed Cronobacter infection. The traditional antibiotic regimen for Cronobacter spp. was ampicillin in combination with either gentamicin or chloramphenicol. In view of claimed resistance to ampicillin and most first- and second-generation cephalosporins, it has been suggested that carbapenems or third-generation cephalosporins be used with an aminoglycoside or trimethoprim/sulfamethoxazole (24). In our study, antimicrobial resistance testing showed susceptibility to all tested antibiotics for 20 of 21 human isolates from 2017. In comparison to other members of the family Enterobacteriaceae, Cronobacter strains seem to be more susceptible against so-called "key access antibiotics" of the World Health Organization's Model List of Essential Medicines (25), such as ampicillin, aminoglycosides, chloramphenicol, and third-generation cephalosporins (the last is included in the List of Essential Medicines only for specific, limited indications) (26). For all isolates, we confirmed the presence of 1 of 4 tested ampC [beta]-lactamase variants, which confer phenotypic resistance exclusively to first-generation cephalosporins (e.g., cephalothin) but not to ampicillin (23). A few studies have reported Cronobacter isolates conferring multidrug resistance (26), a phenomenon observed in our study only for 1 strain from Slovenia.

Correct species identification within the Cronobacter group was a major challenge for 7 of 11 participating laboratories. This identification problem is consistent with numerous misidentifications reported in the literature (27,28). The discrepancies in correct Cronobacter spp. identification on a genus and species level between the study center in Austria and the primary testing laboratories using MALDI-TOF MS is probably attributable to outdated databases used by primary testing laboratories. Nevertheless, our study showed that the overall MALDI-TOF MS performance for Cronobacter spp. identification on the species level is insufficient and misleading. The databases contained data for C. sakazakii only, and therefore all 7 species of the genus Cronobacter were identified as C. sakazakii. In addition, although a database comment indicated that Cronobacter could only be identified on the genus level, the MALDI-TOF MS result simulated the highest identification score for C. sakazakii. This shortfall should be corrected by an update of the MALDI-TOF MS databases to enable accurate Cronobacter identification at the species level. In comparison, WGS-based species identification represents a major improvement to conventional identification methods and MALDI-TOF MS (29). Therefore, we recommend the use of WGS-based identification tools and databases for identification of species within the Cronobacter group.

Adults were the main affected age group in our study. All but 2 of the isolates from 2017 originated from adults. This finding confirms the results from previous recent studies (14,30) and contradicts statements in numerous medical textbooks, postulating that infants are more often affected than adults (8,31-33).

Our study has some limitations. Lack of information (e.g., detailed epidemiologic and clinical patient data) and misidentification on genus and species levels, might have played a role in underestimating the real prevalence rate; 13 of the 24 participating countries did not find or did not submit C. sakazakii isolates.

In conclusion, this C. sakazakii study in Europe revealed a high strain diversity, which points to highly diverse infection sources and an absence of national or multinational outbreaks in 2017. Correct identification of C. sakazakii still poses a diagnostic challenge to many laboratories, and the use of such imperfect detection systems might explain the low prevalence of reported clinical C. sakazakii isolates found in this study. WGS data must be used for accurate species identification and high-resolution strain typing. We recommend the inclusion of C. sakazakii as a notifiable organism by public health authorities.

Members of the EUCRONI study group: F. Allerberger, Austrian Agency for Health and Food Safety, Vienna, Austria; A. Tambic Andrasevic, University Hospital for Infectious Diseases, Zagreb, Croatia; A. Balode, Pauls Stradins Clinical University Hospital, Riga, Latvia; F. Barbut, Hopital Saint-Antoine, Paris, France; Irina Codita, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; M. Cormican, School of Medicine National University of Ireland Galway, Galway, Ireland; C. Ferguson, Victoria Hospital, Kirkcaldy, Scotland, United Kingdom; P. Heczko, Jagiellonian University Medical College, Krakow, Poland; O. Holy, Department of Preventive Medicine, Palacky University Olomouc, Czech Republic; T. Kantardjiev, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria; E.J. Kuijper, Leiden University Medical Center, Leiden, the Netherland; T.M. Leegaard, Akershus University Hospital, Lorenskog, Norway; L.M.V. Peixe, University of Porto, Porto, Portugal; D. Pierard, Department of Laboratory Medicine, Universitair Ziekenhuis Brussel, Belgium; H. Rautelin, Uppsala University, Uppsala, Sweden; M. Rupnik, Nacionalni Laboratorij za Zdravje, Okolje in Hrano, Maribor, Slovenia; K. Schonning, Hvidovre Hospital, Hvidovre, Denmark; R. Stephan, Institute for Food Safety and Hygiene, University of Zurich, Zurich, Switzerland; A. Toniolo, Universita degli Studi dell'Insubria, Varese, Italy; T. Tosic, Clinical Center of Serbia, Belgrade, Serbia; S. Valdezate, Instituto de Salud Carlos III., Madrid, Spain; L. von Muller, Christophorus-Kliniken GmbH, Coesfeld, Germany; L. Zerva, Attikon-Hospital, Athens, Greece; and B. Zinieri-Panayide, General Hospital, Paphos, Cyprus.

Acknowledgments

We thank the following persons for their willingness to provide isolates and information to the national study coordinators: Charlotte Nielsen Agergaard, John Bingham, Nadine Botteldoorn, Carolyn Cameron, Urska Dermota, Harald Dirschmid, Astrid Dopita, Stefan Doppler, Gebhard Feierl, Manfred Fille, Sonja Fischelschweiger, J. Gigi, Maja Gosnjak, Nils Grude, Renee Haunold, Iren Hoyland Lohr, Heidrun Kerschner, Uwe Konig, Helena Ramos, Tanja Vrabic, Slavica Lorencic Robnik, Tatjana Rupel, Helene Marchandin, Helga Masoud, Louise O'Connor, Renata Ocvirk, Christian Petternel, Catherine Potvliege, Christian Salgard Jensen, Gunnar Skov Simonsen, Bettina Titz, Herwig Tomantschger, Martin Totsch, Svetlana Ugarcina Perovic, Birgit Willinger, and Markus Winkler.

This study was initiated and partially funded by ESCMID Food- and Water-borne Infections Study Group.

The authors have no conflict of interests to declare. The institutional review board of the city of Vienna studied the protocol and decided on July 28, 2016, under EK 16-161-VK-NZ that the study did not require formal ethics review.

Ms. Lepuschitz studied molecular biology with a focus on molecular medicine and is currently a PhD student focusing on infectious diseases at the Vienna University of Technology and the Austrian Agency for Health and Food Safety, Vienna, Austria. Her primary research interests include the characterization and epidemiology of clinical, foodborne, and environmental pathogens.

References

(1.) Forsythe SJ, Dickins B, Jolley KA. Cronobacter, the emergent bacterial pathogen Enterobacter sakazakii comes of age; MLST and whole genome sequence analysis. BMC Genomics. 2014;15:1121. http://dx.doi.org/10.n86/1471-2164-15-n21

(2.) Iversen C, Mullane N, McCardell B, Tall BD, Lehner A, Fanning S, et al. Cronobacter gen. nov., a new genus to accommodate the biogroups of Enterobacter sakazakii, and proposal of Cronobacter sakazakii gen. nov., comb. nov., Cronobacter malonaticus sp. nov., Cronobacter turicensis sp. nov., Cronobacter muytjensii sp. nov., Cronobacter dublinensis sp. nov., Cronobacter genomospecies 1, and of three subspecies, Cronobacter dublinensis subsp. dublinensis subsp. nov., Cronobacter dublinensis subsp. lausannensis subsp. nov. and Cronobacter dublinensis subsp. lactaridi subsp. nov. Int J Syst Evol Microbiol. 2008;58:1442-7. http://dx.doi.org/10.1099/ijs.0.65577-0

(3.) Joseph S, Forsythe SJ. Predominance of Cronobacter sakazakii sequence type 4 in neonatal infections. Emerg Infect Dis. 2011;17:1713-5. http://dx.doi.org/10.3201/eid1709.110260

(4.) Kandhai MC, Reij MW, Gorris LG, Guillaume-Gentil O, van Schothorst M. Occurrence of Enterobacter sakazakii in food production environments and households. Lancet. 2004;363:39-40. http://dx.doi.org/10.1016/S0140-6736(03)15169-0

(5.) Lehner A, Stephan R. Microbiological, epidemiological, and food safety aspects of Enterobacter sakazakii. J Food Prot. 2004;67:2850-7. http://dx.doi.org/10.4315/0362-028X-67.12.2850

(6.) Iversen C, Forsythe S. Risk profile of Enterobacter sakazakii, an emergent pathogen associated with infant milk formula. Trends Food Sci Technol. 2003;14:443-54. http://dx.doi.org/10.1016/ S0924-2244(03)00155-9

(7.) European Food Safety Agency. Opinion of the Scientific Panel on Biological Hazards (BIOHAZ) related to the microbiological risks in infant formulae and follow-on formulae. European Food Safety Agency Journal. 2004;113:1-35.

(8.) Lund BM. Properties of microorganisms that cause foodborne disease. In: Lund BM, Hunter PR, editors. The microbiological safety of food in healthcare settings. Oxford: Blackwell Publishing; 2008. p. 12-233.

(9.) Forsythe SJ. Updates on the Cronobacter genus. Annu Rev Food Sci Technol. 2018;9:23-44. http://dx.doi.org/10.1146/ annurev-food-030117-012246

(10.) World Health Organization and Food and Agriculture Organization of the United Nations. Enterobacter sakazakii (Cronobacter spp.) in powdered follow-up formula. Meeting report, Microbiology Risk Assessment Series, No. 15. Geneva: World Health Organization; 2008 [cited 2018 Oct 1. http://www.who.int/foodsafety/ publications/micro/MRA_followup.pdf

(11.) Losio MN, Pavoni E, Finazzi G, Agostoni C, Daminelli P, Dalzini E, et al. Preparation of powdered infant formula: could product's safety be improved? J Pediatr Gastroenterol Nutr. 2018;67:543-6. http://dx.doi.org/10.1097/ MPG.0000000000002100

(12.) Chaves CEV, Brandao MLL, Lacerda MLGG, Rocha CABC, Leone de Oliveira SMDV, Parpinelli TC, et al. Fatal Cronobacter sakazakii sequence type 494 meningitis in a newborn, Brazil. Emerg Infect Dis. 2018;24:1948-50. http://dx.doi.org/10.3201/ eid2410.180373

(13.) Drudy D, Mullane NR, Quinn T, Wall PG, Fanning S. Enterobacter sakazakii: an emerging pathogen in powdered infant formula. Clin Infect Dis. 2006;42:996-1002. http://dx.doi.org/10.1086/501019

(14.) Alsonosi A, Hariri S, Kajsik M, Orieskova M, Hanulik V, Roderova M, et al. The speciation and genotyping of Cronobacter isolates from hospitalised patients. Eur J Clin Microbiol Infect Dis. 2015;34:1979-88. http://dx.doi.org/10.1007/s10096-015-2440-8

(15.) Patrick ME, Mahon BE, Greene SA, Rounds J, Cronquist A, Wymore K, et al. Incidence of Cronobacter spp. infections, United States, 2003-2009. Emerg Infect Dis. 2014;20:1520-3. http://dx.doi.org/10.3201/eid2009.140545

(16.) Lepuschitz S, Sorschag S, Springer B, Allerberger F, Ruppitsch W. Draft genome sequence of carbapenemase-producing Serratia marcescens isolated from a patient with chronic obstructive pulmonary disease. Genome Announc. 2017;5:e01288-17. http://dx.doi.org/10.1128/genomeA.01288-17

(17.) Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455-77. http://dx.doi.org/10.1089/cmb.2012.0021

(18.) Ruppitsch W, Pietzka A, Prior K, Bletz S, Fernandez HL, Allerberger F, et al. Defining and evaluating a core genome MLST scheme for whole genome sequence-based typing of Listeria monocytogenes. J Clin Microbiol. 2015;53:2869-76. http://dx.doi.org/10.1128/JCM.01193-15

(19.) Kucerova E, Clifton SW, Xia XQ, Long F, Porwollik S, Fulton L, et al. Genome sequence of Cronobacter sakazakii BAA-894 and comparative genomic hybridization analysis with other Cronobacter species. PLoS One. 2010;5:e9556. http://dx.doi.org/ 10.1371/journal.pone.0009556

(20.) Richter M, Rossello-Mora R, Oliver Glockner F, Peplies J. JSpeciesWS: a web server for prokaryotic species circumscription based on pairwise genome comparison. Bioinformatics. 2016;32:929-31. http://dx.doi.org/10.1093/bioinformatics/btv681

(21.) Jolley KA, Bliss CM, Bennett JS, Bratcher HB, Brehony C, Colles FM, et al. Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain. Microbiology. 2012;158:1005-15. http://dx.doi.org/10.1099/mic.0.055459-0

(22.) Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 2017;45(D1):D566-73. http://dx.doi.org/10.1093/nar/gkw1004

(23.) Muller A, Hachler H, Stephan R, Lehner A. Presence of AmpC beta-lactamases, CSA-1, CSA-2, CMA-1, and CMA-2 conferring an unusual resistance phenotype in Cronobacter sakazakii and Cronobacter malonaticus. Microb Drug Resist. 2014;20:275-80. http://dx.doi.org/10.1089/mdr.2013.0188

(24.) Lai KK. Enterobacter sakazakii infections among neonates, infants, children, and adults. Case reports and a review of the literature. Medicine (Baltimore). 2001;80:113-22. http://dx.doi.org/10.1097/00005792-200103000-00004

(25.) World Health Organization. The selection and use of essential medicines. Report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children). WHO Technical Report Series, no. 1006. Geneva: The Organization; 2017 [cited 2018 Oct 1]. http://apps.who.int/ medicinedocs/documents/s23371en/s23371en.pdf

(26.) Shi L, Liang Q, Zhan Z, Feng J, Zhao Y, Chen Y, et al. Co-occurrence of 3 different resistance plasmids in a multi-drug resistant Cronobacter sakazakii isolate causing neonatal infections. Virulence. 2018;9:110-20. http://dx.doi.org/10.1080/21505594.20 17.1356537

(27.) Blazkova M, Javurkova B, Vlach J, Goselova S, Karamonova L, Ogrodzki P, et al. Diversity of O antigens within the genus Cronobacter: from disorder to order. Appl Environ Microbiol. 2015;81:5574-82. http://dx.doi.org/10.1128/AEM.00277-15

(28.) Jackson EE, Flores JP, Fernandez-Escartin E, Forsythe SJ. Reevaluation of a suspected Cronobacter sakazakii outbreak in Mexico. J Food Prot. 2015;78:1191-6. http://dx.doi.org/10.4315/ 0362-028X.JFP-14-563

(29.) Yan Q, Fanning S. Strategies for the identification and tracking of Cronobacter species: an opportunistic pathogen of concern to neonatal health. Front Pediatr. 2015;3:38. http://dx.doi.org/10.3389/ fped.2015.00038

(30.) Holy O, Forsythe S. Cronobacter spp. as emerging causes of healthcare-associated infection. J Hosp Infect. 2014;86:169-77. http://dx.doi.org/10.1016/j.jhin.2013.09.011

(31.) Allerberger F, Pichler J, Ohlinger R, Gelpi E, Budka H. Nahrungsmittelbedingte Infektionskrankheiten und Intoxikationen. In: Ledochowski M, editor. Klinische Ernahrungsmedizin. Vienna: Springer-Verlag; 2010. p. 347-408.

(32.) Barer MR, Swann A. Klebsiella, Enterobacter, Proteus and other enterobacteria. In: Barer MR, Irving W, Swann A, Perera N, editors. Medial microbiology--a guide to microbial infections: pathogenesis, immunity, laboratory investigation and control. 19th edition. Oxford: Elsevier Inc.; 2018. p. 198-204.

(33.) Jenkins C, Rentenaar RJ, Landraid L, Brisse S. Enterbacteriaceae. In: Cophen J, Powderly WG, Opal SM, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 8th edition. Atlanta: Elsevier Inc.; 2017. p. 1564-78.

Address for correspondence: Sarah Lepuschitz, Austrian Agency for Health and Food Safety, Institute for Medical Microbiology and Hygiene, Waehringerstrasse 25a, 1090 Vienna, Austria; email: sarah.lepuschitz@ages.at

[1] Members of the EUCRONI study group are listed at the end of this article.

Author affiliations: Austrian Agency for Health and Food Safety, Vienna, Austria (S. Lepuschitz, W. Ruppitsch, S. Pekard-Amenitsch, F. Allerberger); Vienna University of Technology, Vienna (S. Lepuschitz, R.L. Mach); foodmicrobe.com, Keyworth, United Kingdom (S.J. Forsythe); National University of Ireland, Galway, Ireland (M. Cormican); Universitair Ziekenhuis Brussel, Brussels, Belgium (D. Pierard)

DOI: https://doi.org/10.3201/eid2503.181652

Caption: Figure 1. Countries participating in a multicenter study of Cronobacter sakazakii infections in humans, Europe, 2017. Dark green indicates the 8 countries that sent C. sakazakii isolates to the study center in Austria; light green indicates the 3 countries where historical outbreaks were detected; and red indicates the 13 countries that participated but did not provide isolates. AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; FR, France; GR, Greece; HR, Croatia; IE, Ireland; IT, Italy; LV, Latvia; NL, Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SE, Sweden; SI, Slovenia; UK, United Kingdom.

Caption: Figure 2. Minimum-spanning tree of 59 Cronobacter sakazakii isolates, including 21 human isolates from 2017 and 38 historical human isolates, from 11 countries in Europe. Each circle represents isolates with an allelic profile based on the core genome multilocus sequence type, which consists of 2,831 alleles. Blue numbers indicate the allelic differences between isolates; isolates with closely related genotypes are shaded in gray. Isolates were colored according to classical multilocus sequence type, labeled with the country of isolation and the respective sample identification. Nodes encircled with a dotted red line were collected in 2017. Ireland additionally provided 7 historical isolates originating from Canada (n = 4), United States (n = 2), and Switzerland (n = 1). For comparison, sequence data of reference strains ATCC BAA-894 (United States, ST1), ATCC29544 (United States, ST8), and NCTC 8155 (United Kingdom, ST4) were included. ST, sequence type.
Table 1. Comparison of MALDI-TOF mass spectrometry and whole-genome
sequencing results for 77 isolates submitted as Cronobacter sakazakii
in a multicenter study of C. sakazakii infections in humans, Europe,
2017 *

                                                            Total no.
MALDI-TOF                       Whole-genome sequencing     isolates

C. sakazakii                         C. sakazakii              59
C. sakazakii                        C. dublinensis              1
C. sakazakii                        C. malonaticus              5
C. sakazakii                         C. turicensis              2
C. sakazakii                        C. universalis              1
C. sakazakii                    Siccibacter turicensis          1
Enterobacter aerogenes            Kluyvera intermedia           1
E. asburiae                           E. cloacae                2
E. asburiae                           E. asburiae               1
Klebsiella oxytoca                Klebsiella oxytoca            1
Kosakonia cowanii                  Kosakonia cowanii            2
Paenibacillus pasadenensis    Paenibacillus pasadenensis        1

                               Human isolates    Historical human
MALDI-TOF                     detected in 2017       isolates

C. sakazakii                         21                 38
C. sakazakii                         1                  --
C. sakazakii                         4                  1
C. sakazakii                         1                  1
C. sakazakii                         1                  --
C. sakazakii                         1                  --
Enterobacter aerogenes               1                  --
E. asburiae                          2                  --
E. asburiae                          --                 1
Klebsiella oxytoca                   1                  --
Kosakonia cowanii                    2                  --
Paenibacillus pasadenensis           1                  --

* MALDI-TOF, matrix-assisted laser desorption-ionization time-of-
flight; --, no isolates detected.

Table 2. Characteristics of patients enrolled and Cronobacter
sakazakii isolates collected in a multicenter study of C. sakazakii
infections in humans, Europe, 2017 *

Sample ID     Country of origin   Patient age, y/sex

802520             Austria               73/F
7750-17            Austria               <1/M
16862-17           Austria               77/F
808921             Austria               69/F
56487-17           Austria               78/M
101807-17          Austria               77/M
9929-17            Austria               5/M
EUCRONI016         Belgium               61/M
EUCRONI012         Belgium               78/M
1481-17        Czech Republic            80/F
436-17         Czech Republic            31/M
10965-17       Czech Republic            74/M
D97986             Denmark               85/F
17007483           Denmark               69/M
423410             Ireland               65/M
170215-0130        Norway                87/M
M732000           Portugal               60/M
80357408-17       Scotland               73/F
80363028-17       Scotland               71/M
07 2005           Slovenia               54/M
2017C1           Switzerland             55/F

Sample ID      Specimen source    Death within 30 d   MLST

802520              Stool                No           630
7750-17             Blood                Yes           4
16862-17            Blood                No            37
808921              Stool                No            21
56487-17            Urine                No            17
101807-17           Blood                No            1
9929-17             Stool                No            17
EUCRONI016          Urine                No            13
EUCRONI012          Wound                No            31
1481-17          Rectal swab             No            8
436-17           Rectal swab             No            4
10965-17         Rectal swab             No            4
D97986             Sputum                No            1
17007483            Urine                No            58
423410              Blood                No            12
170215-0130         Blood                Yes           17
M732000             Urine                No            40
80357408-17         Stool                No            33
80363028-17         Urine                No            4
07 2005       Tracheal aspirate          No           184
2017C1          Cervix uteri             No            40

* MLST, multilocus sequence type.

Table 3. In silico evaluation of MLSTs for Cronobacter sakazakii
strains in a multicenter study of C. sakazakii infections in humans,
Europe, 2017 *

                                      Historical
       Total no.    Human isolates      human
MLST   isolates    detected in 2017    isolates

1          7              2               5
12         1              1               --
13         1              1               --
148        1              --              1
155       10              --              10
17         3              3               --
184        1              1               --
21        10              1               9
31         2              1               1
33         1              1               --
37         1              1               --
4         11              4               7
40         2              2               --
50         1              --              1
58         1              1               --
630        1              1               --
8          5              1               4

* MLST, multilocus sequence type; --, no isolates detected.
COPYRIGHT 2019 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH
Author:Lepuschitz, Sarah; Ruppitsch, Werner; Pekard-Amenitsch, Shiva; Forsythe, Stephen J.; Cormican, Marti
Publication:Emerging Infectious Diseases
Geographic Code:4EUIR
Date:Mar 1, 2019
Words:5266
Previous Article:Simplified Model to Survey Tuberculosis Transmission in Countries without Systematic Molecular Epidemiology Programs.
Next Article:Window Period Prophylaxis for Children Exposed to Tuberculosis, Houston, Texas, USA, 2007-2017.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters